Details

Autor(en) / Beteiligte

• Schallenberg, Simon
• Plage, Henning
• Hofbauer, Sebastian
• Furlano, Kira
• Weinberger, Sarah
• Bruch, Paul Giacomo
• Roßner, Florian
• Elezkurtaj, Sefer
• Kluth, Martina
• Lennartz, Maximilian
• Blessin, Niclas C.
• Marx, Andreas H.
• Samtleben, Henrik
• Fisch, Margit
• Rink, Michael
• Slojewski, Marcin
• Kaczmarek, Krystian
• Ecke, Thorsten
• Hallmann, Steffen
• Koch, Stefan
• Adamini, Nico
• Minner, Sarah
• Simon, Ronald
• Sauter, Guido
• Horst, David
• Klatte, Tobias
• Schlomm, Thorsten
• Zecha, Henrik

Titel

Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors

Ist Teil von

• Acta oncologica, 2023-12, Vol.62 (12), p.1880-1889

Erscheinungsjahr

2023

Quelle

Taylor & Francis

Beschreibungen/Notizen

• BACKGROUNDMost inactivating p53 mutations result in a nuclear p53 accumulation - detectable by immunohistochemistry (IHC). p53 alterations leading to a complete lack of p53 protein and absence of immunostaining do also occur - not easily detectable by IHC. p16 is upregulated in p53 inactivated cells. We hypothesized that a positive p16 IHC may help to distinguish p53 inactivation in IHC negative cases.MATERIAL AND METHODSWe investigated p53 and p16 immunostaining on 2710 urothelial bladder carcinomas in a tissue microarray format to understand their impact in relation to clinicopathological parameters of disease progression and patient outcome.RESULTSp16 immunostaining was absent in normal urothelium but occurred in 63.5% (30.4% strong) of cancers. p16 strongly positive cases increased from pTaG2 low-grade (9.6%) to pTaG3 high-grade tumors (46.5%, p < .0001) but decreased from pTaG3 to pT4 (33.3%; p = .0030). Among pT2-4 carcinomas, p16 positivity was linked to high-grade (p = .0005) but unrelated to overall survival. p53 staining was negative in 8.4%, very weak in 15.4%, weak in 55.3%, strong in 4.7%, and very strong in 16.2% cancers. p53 negative (potentially p53 null phenotype), strong, and very strong p53 positivity increased from pTaG2 low-grade to pTaG3 high-grade tumors (p < .0001) and from pTaG3 to pT2-4 cancers (p = .0007). p53 staining was largely unrelated to histopathological parameters or patient prognosis among pT2-4 carcinomas, except of p53 strong/very strong immunostaining. p16 expression predominated in tumors with very strong, strong, and negative p53 staining and the combination of p53 negative/p16 strongly positive cancers was linked to features of tumor aggressiveness.CONCLUSIONAberrant p53 and p16 immunostaining increases during grade and stage progression although p53 negative and p16 positive immunostaining lack prognostic significance in pT2-4 carcinomas. Potential diagnostic features are that high level p16 expression is limited to neoplastic urothelium and p53 null phenotype to aggressive cancers (grade 3 and invasive).